Novavax President of R&D Dr. Gregory Glenn to retire effective March 31, 2023

NOVAVAX INC

Dr. Gregory M. Glenn notified Novavax of his retirement as President, Research and Development.
Retirement effective March 31, 2023; he will become Strategic Research & Development Advisor.
No successor named in the filing; consulting services to follow retirement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Gregory M. Glenn

President, Research and Development

NVAX · NOVAVAX INC

Effective: 2023-03-31
Filed: March 2, 2023, 6:59 PM ET

On February 28, 2023, Dr. Gregory M. Glenn, M.D. notified Novavax Inc. (the “Company”) of his decision to retire as President, Research and Development, effective as of March 31, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Gregory M. Glenn retired as President, Research and Development at NOVAVAX INC.

Action: retired
Role: President, Research and Development

Exact text from the filing

On February 28, 2023, Dr. Gregory M. Glenn, M.D. notified Novavax Inc. (the “Company”) of his decision to retire as President, Research and Development, effective as of March 31, 2023.

View on SEC.gov

NOVAVAX INC filing history →

Source: SEC EDGAR

accession 0001104659-23-028031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.